[144] Arcus Biosciences, Inc. SEC Filing

Rhea-AI Filing Summary

Arcus Biosciences (RCUS) holder filed a Form 144 to sell 1,173 shares of Class A Common Stock with an aggregate market value of $23,682.87, approximately on October 30, 2025, through Goldman Sachs & Co. LLC on the NYSE.

The notice also lists recent sales by the same account: 19,019 shares for $383,944.16 on October 28, 2025; 76,667 shares for $1,600,791.63 on October 29, 2025; 1,173 shares for $25,844.94 on October 29, 2025; and 3,141 shares for $63,817.27 on October 30, 2025. Shares outstanding were 107,973,536; this is a baseline figure, not the amount being sold.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Common Stock	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	1173	23682.87	107973536	10/30/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Common Stock	05/29/2015	Acquired from issuer in private transaction	The Issuer			1173	05/29/2015	None

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
The Juan Carlos Jaen and Anita Galeana 2000 Trust 3928 Point Eden Way Hayward CA 94545	Class A Common Stock	10/28/2025	19019	383944.16
The Juan Carlos Jaen and Anita Galeana 2000 Trust 3928 Point Eden Way Hayward CA 94545	Class A Common Stock	10/29/2025	76667	1600791.63
The Juan Carlos Jaen and Anita Galeana 2000 Trust 3928 Point Eden Way Hayward CA 94545	Class A Common Stock	10/29/2025	1173	25844.94
The Juan Carlos Jaen and Anita Galeana 2000 Trust 3928 Point Eden Way Hayward CA 94545	Class A Common Stock	10/30/2025	3141	63817.27

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many RCUS shares are planned for sale under this Form 144?

The notice covers 1,173 shares of Class A Common Stock.

What is the aggregate market value of the RCUS shares to be sold?

The aggregate market value listed is $23,682.87.

When is the approximate sale date for the RCUS shares?

The approximate sale date is October 30, 2025.

Which broker is handling the proposed RCUS share sale?

The broker is Goldman Sachs & Co. LLC.

On which exchange will the RCUS shares be sold?

The filing names the NYSE.

How many RCUS shares were outstanding, as referenced in the notice?

Shares outstanding were listed as 107,973,536.

What RCUS shares were sold by the filer in the prior three months?

Disclosed sales include 19,019 for $383,944.16 (Oct 28), 76,667 for $1,600,791.63 (Oct 29), 1,173 for $25,844.94 (Oct 29), and 3,141 for $63,817.27 (Oct 30), all in 2025.